Post-operative treatment with cisplatin and vinorelbine in chinese patients with non-small cell lung cancer: A clinical prospective analysis of 451 patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 9, 2012, Pages 4505-4510

  Wang, Jing ^a   Liu, Feng ^a   Huang, Deng Xiao ^a   Jiang, Bin ^a  

^a School of Medicine   (China)

Author keywords

cisplatin; Non small cell lung cancer; survival; vinorelbine

Indexed keywords

EID: 84874001908     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.9.4505     Document Type: Article

References (33)

1. Andrews J, Yeh P, Pao W, et al (2011). Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J, 17, 104-13.
2. Arriagada R, Bergman B, Dunant A, et al (2004). International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350, 351-60.
3. Arriagada R, Dunant A, Pignon JP, et al (2010). Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 28, 35-42.
4. Banna GL, Di Maio M, Follador A, et al (2011). Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). Lung Cancer, 73, 78-88.
5. Bennouna J, Senellart H, Hiret S, et al (2011). Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer, 74, 30-4.
6. Butts CA, Ding K, Seymour L, et al (2010). Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol, 28, 29-34.
7. Cella D, Huang HQ, Monk BJ, et al (2010). Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol, 119, 531-7.
8. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group (1995). BMJ, 311, 899-909.
9. Chen SE, Pace MB (2012). Malignant pleural mesothelioma. Am J Health Syst Pharm, 69, 377-85.
10. Devleena, Majumdar A, Poddar S, et al (2010). Comparison of vinorelbine with cisplatin in concomitant chemoradiotherapy in head and neck carcinoma. Indian J Med Paediatr Oncol, 31, 4-7.
11. Douillard JY, Rosell R, De Lena M, et al (2006). Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 7, 719-27.
12. Douillard JY, Tribodet H, Aubert D, et al (2010). LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol, 5, 220-8.
13. Früh M, Rolland E, Pignon JP, et al (2008). Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol, 26, 3573-81.
14. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
15. Guo L, Bai SP, Zhao L, et al (2011). Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol, 29, 1656-62.
16. Hotta K, Matsuo K, Ueoka H, et al (2004). Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol, 22, 3860-7.
17. Hu Z, Chen X, Zhao Y, et al (2010). Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol, 28, 1721-6.
18. Imaizumi M (2005). Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer, 49, 85-94.
19. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics. CA Cancer J Clin, 56, 106-30.
20. Jemal A, Siegel R, Ward E, et al (2007). Cancer statistics. CA Cancer J Clin, 57, 43-66.
21. Klastersky J, Awada A (2012). Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol, 81, 49-57.
22. Long SQ, Liao GY, He WF, et al (2011). Influence of Shenfu Injection on the quality of life of lung cancer patients receiving chemotherapy. Nan Fang Yi Ke Da Xue Xue Bao, 31, 2090-2.
23. Nakagawa K, Tada H, Akashi A, et al (2006). Osaka Lung Cancer Study Group, Japan. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer, 95, 817-21.
24. Pignon JP, Tribodet H, Scagliotti GV, et al (2008). LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 26, 3552-9.
25. Pouessel D, Huguet H, Iborra F, et al (2010). A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer. Anticancer Res, 30, 4711-5.
26. Quoix E, Ramlau R, Westeel V, et al (2011). Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol, 12, 1125-33.
27. Scagliotti GV, Fossati R, Torri V, et al (2003). Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst, 95, 1453-61.
28. Shamseddine AI, Farhat FS (2011). Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy, 57, 468-87.
29. Strauss GM, Herndon JE, Maddaus MA, et al (2008). Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol, 26, 5043-51.
30. Vale CL, Thompson LC, Murphy C, et al (2012). Involvement of consumers in studies run by the Medical Research Council (MRC) Clinical Trials Unit: Results of a survey. Trials, 13, 9.
31. Voortman J, Goto A, Mendiboure J, et al (2010). MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res, 70, 8288-98.
32. Waller D, Peake MD, Stephens RJ, et al (2004). Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg, 26, 173-82.
33. Winton T, Livingston R, Johnson D, et al (2005). National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 352, 2589-97.